@article{7fda70ed2d1d4259b673a6b012098d1e,
title = "Sex Differences in Heart Failure",
abstract = "Heart failure (HF) continues to be a major contributor of morbidity and mortality for men and women alike, yet how the predisposition for, course and management of HF differ between men and women remains underexplored. Sex differences in traditional risk factors as well as sex-specific risk factors influence the prevalence and manifestation of HF in unique ways. The pathophysiology of HF differs between men and women and may explain sex-specific differences in clinical presentation and diagnosis. This in turn, contributes to variation in response to both pharmacologic and device/surgical therapy. This review examines sex-specific differences in HF spanning prevalence, risk factors, pathophysiology, presentation, and therapies with a specific focus on highlighting gaps in knowledge with calls to action for future research efforts.",
keywords = "Heart failure, cardiovascular disease, sex differences, women",
author = "ANURADHA Lala and UPASANA TAYAL and HAMO, {CARINE E.} and Youmans, {Quentin Riggins} and AL-KHATIB, {SANA M.} and BIYKEM BOZKURT and DAVIS, {MELINDA B.} and JAMES JANUZZI and ROBERT MENTZ and ANDREW SAUER and WALSH, {MARY NORINE} and CLYDE YANCY and MARTHA GULATI",
note = "Funding Information: AL: Speaker fees/Honoraria from Zoll, Abbott, Bioventrix, and Susquana. UT: none. CH: none. QY: none. SA: Research funding from Medtronic, Boston Scientific, and Abbott. BB: Consulting fees from scPharmaceuticals, Relypsa, and Amgen; and serves on the Clinical Event Committee for GUIDE HF Trial sponsored by Abbott Vascular, and Data Safety Monitoring Committee of ANTHEM trial sponsored by Liva Nova. MD: none. JJ: Dr. Januzzi is a Trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; has received grant support from Abbott Diagnostics, Applied Therapeutics, Innolife and Novartis; has received consulting income from Abbott Diagnostics, Boehringer-Ingelheim, Janssen, Novartis, Roche Diagnostics; and participates in clinical end point committees/data safety monitoring boards for AbbVie, Siemens, Takeda and Vifor. RM: Research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim/Eli Lilly, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. AS: Speaking/consulting fees from Abbott, Medtronic, Boston Scientific, and Impulse Dynamics. MNW: Consulting fees from EBR Systems. CY: none. MG: none. Funding Information: SA: Research funding from Medtronic, Boston Scientific, and Abbott. Publisher Copyright: {\textcopyright} 2021",
year = "2022",
month = mar,
doi = "10.1016/j.cardfail.2021.10.006",
language = "English (US)",
volume = "28",
pages = "477--498",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "3",
}
